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Multiple sclerosis (MS) is assumed to be an autoimmune disease initiated by autoreac-
tiveT cells that recognize central nervous system antigens. Although adaptive immunity is
clearly involved in MS pathogenesis, innate immunity increasingly appears to be implicated
in the disease. We and others have presented evidence that natural killer (NK) cells may be
involved in immunoregulation in MS, leading to the question of whether a particular NK cell
subtype will account for this effect. Changes of NK cell functionality in MS were associated
with MS activity, and depletion of NK cells exacerbated the course of disease in a murine
model of MS, experimental autoimmune encephalomyelitis. Several studies described a
deficiency and transient “valleys” in NK cell killing activity in human MS, which may coin-
cide with symptomatic relapse. However, the molecular basis of the defect in killing activity
has not been determined. We discuss results on the expression of perforin in CD16+ NK
cells and the existence of an inverse relationship between myelin loaded phagocytes and
the proportion of CD16+ NK cells expressing perforin in the circulation. This inverse rela-
tionship is consistent with a role for NK cell killing activity in dampening autoimmunity. On
the other hand, it has been broadly reported that first line MS therapies, such as interferon-
beta, glatiramer acetate as well as escalation therapies such as fingolimod, daclizumab,
or mitoxantrone seem to affect NK cell functionality and phenotype in vivo. Therefore, in
this review we consider evidence for the immunoregulatory role of NK cells in MS and its
animal models. Furthermore, we discuss the effect of MS treatments on NK cell activity.
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INTRODUCTION
Multiple sclerosis (MS) is the most common autoimmune disease
of the central nervous system (CNS) leading to severe disability
in young adults. It is considered to be initiated by autoreactive T
cells that recognize CNS antigens and, in concert with numerous
immune cells, orchestrate an inflammatory reaction which even-
tually results in demyelination and neuroaxonal damage (Aktas
et al., 2007). Recently, the role of innate immunity in the patho-
genesis of MS has attracted more attention and studies on the role
of natural killer (NK) cells are appearing in the literature (Gandhi
et al., 2010).
It is widely accepted that NK cells have two key functions,
namely cytotoxicity and cytokine secretion and are considered to
be mediated by two major NK cell subsets that can be phenotypi-
cally distinguished by the expression of CD56 and CD16 antigens
in humans (Ferlazzo and Munz, 2004; Strowig et al., 2008). More
recently, further markers were shown to distinguish between dif-
ferent maturation subsets. We showed that CX3CR1− NK cells
were immature NK cells and that the chemokine receptor CX3CR1
may serve in combination with CD56, CD57, CD62L, and CD27
to define different steps of NK cell maturation (Hamann et al.,
2011). The NK cell maturation and receptor expression profile is
depicted in Figure 1.
CD56dimCD16+ “mature” NK cells represent about 90% of
total peripheral blood NK cells and are efficient killer cells which
are able to secrete variable levels of interferon (IFN)-γ depending
on the stimuli. CD56bright CD16− “immature” NK cells consti-
tute less than 10% of total blood NK cells and are able to produce
large amounts of cytokines upon stimulation,but develop cytolytic
activity only after prolonged stimulation (Strowig et al., 2008).
These “immature” NK cells are however enriched in secondary
lymphoid tissues (Ferlazzo et al., 2004) and sites of inflammation
(Dalbeth et al., 2004). Interestingly in the neuron-immunologic
context of MS, we recently discovered that contrary to blood NK
cells, NK cells trafficking to the CSF display a phenotype char-
acteristic for a very early stage of maturation (Hamann et al.,
2012).
NK CELLS IN THE PATHOGENESIS OF EXPERIMENTAL
ALLERGIC ENCEPHALOMYELITIS
Experimental Allergic Encephalomyelitis (EAE) is an induced ani-
mal model that mimics some features of MS (Constantinescu
et al., 2011), therefore providing potentially useful insights into the
pathogenesis of this disease. For instance, the potential for treating
MS with blocking antibodies to the adhesion molecule VLA4 was
first demonstrated in the EAE model and has ultimately resulted
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FIGURE 1 | Maturation profile of human and murine NK cells, representing major NK cell markers. pNK, precursor NK cells; iNK, immature NK cells; mNK,
mature NK cells.
in the extremely effective disease-modifying MS drug natalizumab
(discussed in more detail below).
It is well established that EAE is induced by CD4+ T cells
specific for myelin antigens. However, demyelination is a result
of complex interactions among encephalitogenic, regulatory, and
accessory cell populations and factors produced by these cells. The
outcome of the disease depends on which components become
dominant. Animal studies have clearly shown that EAE is regu-
lated in a complex way, and that a given component can have
very different effects depending on the local microenvironment
in which it acts (Morandi et al., 2008). This may explain why NK
cells have been reported to both increase and decrease the severity
of EAE.
Shi et al. (2000) demonstrated that MOG failed to induce EAE
in IL-18 knock-out mice. Features of EAE could be restored upon
IL-18 administration but disease required the presence of IFN-γ-
producing NK cells. In contrast, Zhang et al. (1997) have reported
that in vivo NK cell depletion resulted in exacerbation of clini-
cal symptoms in wild-type C57BL/6 mice. In addition, they also
found that depletion of NK cells resulted in an increased sever-
ity of symptoms when disease was induced by passive transfer
of a MOG-specific T cell line. Furthermore, Xu et al. (2005)
reported that EAE is exacerbated by NK cell depletion and that
NK cells in PLP induced EAE exert a direct cytotoxic effect on
autoantigen-specific, encephalitogenic T cells. Moreover, NK cells
expansion (after IL-2 monoclonal antibody complexes injection)
attenuated EAE and reduced production of CD4+ Th17 in the
CNS (Hao et al., 2011). The observations of Xu et al. may be
particularly relevant to the pathogenesis of MS.
NK CELLS IN THE PATHOGENESIS OF MULTIPLE SCLEROSIS
The vast majority of studies on the immunopathogenesis of MS
have focused on the role of T cells. However, research reports
spanning more than three decades have established that there is
a significant role of NK cells in relapsing–remitting MS (RRMS)
patients (Benczur et al., 1980; Merrill et al., 1982; Neighbour et al.,
1982; Oger et al., 1988; Kastrukoff et al., 1998,2003; Infante-Duarte
et al., 2005; Hamann et al., 2012). Activated NK cells are capable
of cytolysis of autologous oligodendrocytes and are found in acute
inflammatory lesions. In MS however, most studies report a defi-
ciency of NK cytolytic activity in peripheral blood (Benczur et al.,
1980; Merrill et al., 1982; Neighbour et al., 1982; Oger et al., 1988;
Kastrukoff et al., 1998, 2003). These studies employ the in vitro
chromium51 release assay using K562 tumor cells as the target.
In 1980, Benczur et al. (1980) reported that NK cytolytic activ-
ity against K562 targets was significantly low in MS patients and
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most particularly so in male patients with a definitive diagnosis of
MS. This finding of diminished NK cell-mediated cytotoxicity was
quickly reproduced (Merrill et al., 1982; Neighbour et al., 1982).
Oger et al. (1988) performed a small longitudinal study and
found that patients with large asymptomatic MRI lesions had
reduced NK cytolytic activity which subsequently increased as
the MRI lesions diminished. Moreover, we reported an elevated
frequency of immature circulating CX3CR1− NK cells in stable
but not in active MS patients (Infante-Duarte et al., 2005) sup-
porting the role of particular NK cell subsets in mediating relapse
and remission. Furthermore, Kastrukoff et al. (1998, 2003) have
performed longitudinal studies of NK cytolytic activity in RRMS
subjects and have demonstrated “valleys” in killing activity that
last 4–5 weeks. These transient deficits in cytolytic activity may
explain why some studies failed to detect diminished NK cytolytic
activity. More important however is their finding of a significant
correlation between valleys in NK cell killing activity and new or
enlarging active lesions on MRI as well as with clinical exacer-
bations. These authors concluded that valleys in NK cell killing
activity represent periods of susceptibility for the development of
active lesions on MRI and clinical attacks and that these valleys are
the result of cells with an NK phenotype being unable to deliver a
“lethal” hit to targets (Kastrukoff et al., 2003).
These studies fit well with reports that NK cell depletion
exacerbates disease activity in EAE in rodents.
EFFECTS OF CURRENT AND EMERGING MS THERAPIES ON
NK CELLS
Since the first documented case of MS in the nineteenth century,
treatments have evolved in parallel with the emerging understand-
ing of the disease. In the 1860s, Dr. Charcot’s trial to treat MS
patients with gold and silver proved unsuccessful (Clanet, 2008).
Over 150 years later, the spectrum of MS therapies has evolved
to target the major immunopathological players of the disease, T
and B cells (Bar-Or, 2008). However, our comprehension of MS is
still far from complete and further immunological aspects of the
disease, such as involvement of innate immunity and in particular
NK cells, have begun to arouse interest.
Although there is still no cure for MS, a range of disease-
modifying therapies are available for treating patients. These thera-
pies diminish the risk of relapse but exert limited effects in delaying
the progression of disability (Lim and Constantinescu, 2010).
Despite the broadening spectrum of available therapies for MS in
the past few years, there nevertheless remains a lack of selectivity
in the available treatments, leading to serious side effects. Cur-
rently, the principal approved disease-modifying therapies include
IFN-β, glatiramer acetate (GA), natalizumab, fingolimod, mitox-
antrone (Lim and Constantinescu, 2010), and the very recently
approved teriflunomide (Nordqvist, 2012). MS immunomodula-
tory therapies principally benefit RRMS patients, but have been
revealed to be ineffective for patients with progressive forms of the
disease. Moreover, several new therapies with a variety of actions
are currently being tested in phase III clinical trials, including the
oral treatments dimethyl fumarate (NCT00420212) and laquini-
mod (NCT01047319); and the monoclonal antibodies daclizumab
(NCT01064401), rituximab (NCT00087529), and alemtuzumab
(NCT00548405).
Natural Killer cells are being recognized as a hitherto
unexplored player in MS pathogenesis. Thus, the investigation
of how different treatments influence NK cell immunology is
becoming important in understanding drug-related mechanisms
of action and for dissecting out the involvement of NK cells and
their subsets in autoimmune neuroinflammation. The principal
MS therapies and their modes of action are summarized in Table 1.
EFFECTS OF APPROVED MS THERAPIES ON NK CELLS
FIRST LINE THERAPIES: IFN-β AND GA
Interferon-β has become a worldwide standard in the treatment of
MS. It has immunomodulatory properties, and has been shown to
inhibit T cell proliferation, and to impair the trafficking of inflam-
matory cells into the CNS (Yong, 2002; Lim and Constantinescu,
2010). IFN-β appears to induce a slight decrease of total circulat-
ing NK cells in MS patients. Moreover, several studies have shown
a marked expansion in the proportion of the immunoregulatory
NK cell subset CD56bright coupled with a decrease of the cytotoxic
CD56dim NK cells in the periphery following IFN-β therapy (Perini
et al., 2000; Saraste et al., 2007; Vandenbark et al., 2009; Martinez-
Rodriguez et al., 2010). IFN-β is a potent antiviral mediator. Thus,
the expansion of CD56bright NK cells by IFN-β might be related
to the enhancement of NK cell functions following the antiviral
status induced by this therapy (Kastrukoff et al., 1999; Hartrich
et al., 2003). It has been reported that expansion of CD56bright NK
cell and of the inhibitory NK cell receptor NKG2A in blood in
MS patient, as well as reduction of both NK cells markers LILRB1
and KIR could be linked to IFN-β treatment, and more specifi-
cally to positive clinical outcome (Martinez-Rodriguez et al., 2010,
2011). These results suggest that enhancement of NK cell activity
may represent an additional mechanism of action of IFN-β in
MS (Martinez-Rodriguez et al., 2011). Altogether, these findings
suggest that NK cell maturation phenotype is related to the thera-
peutic benefit of IFN-β, although NK cell could not yet be used as
biomarker for response to this therapy.
Glatiramer acetate is a random synthetic polymer composed of
four amino acids that are found in myelin basic protein. GA has
been reported to promote the development of antigen-presenting
cells showing anti-inflammatory properties, such as monocytes
(Weber et al., 2007) and dendritic cells (Moretta, 2002). Since
bilateral actions between antigen-presenting cells and NK cells
have been demonstrated (Ferlazzo et al., 2002; Moretta, 2002;
Degli-Esposti and Smyth, 2005), it has been hypothesized that GA
modulates NK cell functional via antigen-presenting cells. In the
animal model of MS, GA-treated mice displayed a higher killing
efficiency of their NK cells against dendritic cells (Al-Falahi et al.,
2009). However, GA did not have a direct effect on NK cells acti-
vation (Al-Falahi et al., 2009). Similarly, GA enhanced NK cell
cytolysis against dendritic cells in MS patients, without affecting
levels of NK cell activating markers such as NKG2D, NKp30, or
NKp44 (Sand et al., 2009). Thus, GA seems to influence dendritic
cell susceptibility to NK cell cytotoxicity.
SECOND LINE THERAPIES: MITOXANTRONE, NATALIZUMAB,
FINGOLIMOD, AND TERIFLUNOMIDE
Thus far, only a very limited number of treatments are available
for patients with progressive MS. The potent immunosuppressive
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Table 1 | Overview of the effect of current and emerging MS therapies on NK cells.
Treatment Mode of action Effects on NK cells Induced NK cell
phenotype
APPROVEDTHERAPIES
IFN-β Broad Decrease of total circulating NK cells in MS patients Immature
Expansion of immunoregulatory CD56bright/decrease of the cytotoxic CD56dim
NK cells in the periphery (Perini et al., 2000; Saraste et al., 2007; Vandenbark
et al., 2009; Martinez-Rodriguez et al., 2010)
Glatiramer acetate APC-P Influence dendritic cell susceptibility to promote NK cell cytotoxicity (Al-Falahi
et al., 2009; Sand et al., 2009)
unk.
Mitoxantrone IS Indirect NK cell enrichment, due to the depletion of other lymphocyte
population such as B cells
Mature
NK cell maturation only in responders to treatment (Chanvillard et al., 2012)
Natalizumab TI MS: increase of total NK cells and CD56bright NK cells in blood (Putzki et al.,
2010; Skarica et al., 2011)
Immature
EAE: treatment reduced NK cell numbers in spleen, lymph nodes, and CNS,
comparing with non-treated mice (Gan et al., 2012)
Treatment broad impact on NK cell trafficking (Gan et al., 2012)
Fingolimod TI Diverging results on total NK cells in circulation Mature
Decreased CD56bright CD62L+ NK cell proportions in blood
Lymph node egress of immature NK cells blocked (Johnson et al., 2011)
Increased NK cell numbers in CSF of treated patients (Kowarik et al., 2011)
Teriflunomide AM Peripheral NK cell expansion from abnormally low initial values in RA patients
(Manda et al., 2009)
unk.
ON-GOINGTRAILS
Daclizumab LD Higher bioavailability of IL-2 cytokine leading to a large expansion of the NK cell
population (Martin et al., 2010; Hao et al., 2011)
Immature
Expansion of the CD56bright NK cell in the blood, correlating with a positive
response to the treatment (Bielekova et al., 2009)
Expansion of CD56bright NK cells in the CSF of treated patients (Bielekova et al.,
2011)
Alemtuzumab LD Pivotal role of ADCC by NK cells in tumor treatments using monoclonal
antibodies
Immature
Depletion of B and T lymphocytes from the circulation of alemtuzumab treated
mice. Cells with little expression of CD52 such as mature NK cells were
comparably less affected (Hu et al., 2009)
Alemtuzumab activity ablated by NK cell depletion, indicating a prominent role
for NK cell-mediated ADCC in lymphocyte depletion
Rituximab BD ADCC by NK cells previously described to be an essential therapeutic
mechanism of rituximab in lupus treatment (Anolik et al., 2003)
Rituximab clinical outcome in cancer associated with a polymorphism inducing
a variation of the FcgRIII receptor affinity (Veeramani et al., 2011)
unk., unknown; APC-P, antigen-presenting cell promotion; IS, immunosuppressive; TI, T cell inhibition; AM, antimetabolites; LD, leukocyte depletion; BD, B cell
depletion.
agent mitoxantrone is one of these. However, its use is limited
by the appearance of severe side effects. Apart from its general
cytotoxic properties, the mode of action of mitoxantrone on the
immune system is poorly understood. We have recently shown
that mitoxantrone treatment promoted an indirect NK cell enrich-
ment, due to the depletion of other lymphocyte population such
as B cells. Importantly, we have discovered that prolonged treat-
ment with mitoxantrone induced NK cell maturation, occurring
only in those patients that showed a clinical response to treatment
(Chanvillard et al., 2012).
Natalizumab was designed to prevent leukocyte accumulation
in the CNS of EAE (Kent et al., 1995; Yednock et al., 1995), and is
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the first humanized monoclonal antibody approved for treatment
of the relapsing–remitting form of MS (Miller et al., 2003). Natal-
izumab is directed against the very-late antigen-4 integrin, which
has a crucial role in the transmigration of immune cells across
the blood–brain barrier (Ransohoff,2007). Following natalizumab
treatment, total NK cells (Putzki et al., 2010; Planas et al., 2012) as
well as CD56bright NK cells were reported to increase in peripheral
blood of patients (Skarica et al., 2011). In EAE, Gan and colleagues
reported that natalizumab treated mice had lower numbers of NK
cells in the peripheral lymphatic system (spleen and lymph nodes)
and in the CNS, compared to non-treated mice. These findings
suggest that natalizumab may exert a broad impact on the traffick-
ing of NK cells (Gan et al., 2012). Thus, the increase in circulating
CD56bright NK cells in MS patients could be due to NK cell migra-
tion from the lymphoid organs, where the CD56bright subset is
mainly present, to the circulation. Likewise, their entry into the
CNS seems to be blocked. Whether such altered distribution of
NK cells has an impact on the therapeutic effects of natalizumab
remains unknown.
Fingolimod is an oral compound approved for the treatment
of MS. It is a sphingosine 1-phosphate receptor agonist with
demonstrated efficacy in reducing inflammatory events in the
CNS of MS patients (Kappos et al., 2006). Upon phosphoryla-
tion in vivo, fingolimod rapidly inhibits lymphocyte egress from
lymph nodes, therefore preventing access of activated autoreac-
tive T cells to the CNS. Interestingly, despite divergent results
on total NK cells in circulation (Vaessen et al., 2006; Kowarik
et al., 2011), fingolimod treatment decreased the proportions of
circulating CD56brightCD62L+ NK cells, without modulating its
capacity to produce IFN-γ, tumor necrosis factor (TNF)-α, and
IL-10. Within the lymph nodes, about 90% of the NK cells dis-
play an immature CD56brightCD62L+ phenotype. Thus similarly
to the action on T cells, fingolimod seems to block the egress of
immature NK cells from the lymph nodes (Johnson et al., 2011).
Moreover, fingolimod was found to increase NK cell numbers in
CSF of treated patients (Kowarik et al., 2011).
Teriflunomide, the active compound of leflunomide, is an oral
drug that was very recently approved by the FDA for MS treat-
ment in the USA. Leflunomide is licensed for the treatment of
rheumatoid arthritis and is also effective in experimental autoim-
mune neuritis and EAE (Korn et al., 2001, 2004). Although few
studies have been reported in MS so far, peripheral NK cells have
been shown to expand from abnormally low initial values in RA
patients (Manda et al., 2009).
EFFECTS OF EMERGING MS THERAPIES ON NK CELLS
Several immunomodulatory therapies are currently being tested
for their safety and efficacy in controlling brain inflammation and
preventing disease progression in MS.
DACLIZUMAB
Daclizumab is a humanized monoclonal antibody currently in
phase III clinical trials for MS. Daclizumab significantly inhibits
the appearance of lesions and improve clinical scores (Bielekova
et al., 2004, 2009). This treatment was originally given to block the
high affinity IL-2 receptor subunit (CD25), a crucial component
of T cell proliferation and activation. The action of daclizumab
has also been related to a higher bioavailability of IL-2 cytokine,
unexpectedly leading to a large expansion of the NK cell popula-
tion (Martin et al., 2010; Hao et al., 2011). Daclizumab treatment
was reported to induce an expansion of the CD56bright NK cell sub-
set in the blood of MS patients (Bielekova et al., 2006). Moreover,
this increase correlated with a positive response to the treatment
(Bielekova et al., 2009). The expansion of circulating CD56bright
NK cells was associated with decreased brain lesions (Wynn et al.,
2010) and inflammation and reduced survival of activated T cells
(Bielekova et al., 2004, 2006, 2011). Interestingly, it was recently
shown that daclizumab treatment led to a significant expansion
of CD56bright NK cells also in the CSF of treated patients, sug-
gesting that NK cells can suppress immune responses directly
in the CNS (Bielekova et al., 2011). NK cells, along with lym-
phoid tissue-inducer cells (LTi), were described to belong to the
innate lymphoid cells (ILCs), a novel family of developmentally
related hematopoietic effectors that serve protective roles in innate
immune responses (Spits and Di Santo, 2011; Spits et al., 2013).
Recently, daclizumab therapy was reported to shift ILCs precursors
away from LTi phenotype and toward an NK cell lineage. Mech-
anistic studies indicated that daclizumab inhibited differentiation
of LTi indirectly, directing their differentiation toward CD56bright
NK cells through enhanced intermediate-affinity IL-2 signaling
(Perry et al., 2012).
The specific expansion of CD56bright NK cells in contrast to the
CD56dim subset could be explained by their relative expression of
the intermediate-affinity IL-2 receptor: CD122. Indeed, this IL-2
receptor is expressed at least 10-fold more by the CD56bright subset
compared to CD56dim cells (Bielekova et al., 2006). Therefore, this
high expression of intermediate-affinity was hypothesized to allow
CD56bright NK cells to sustain their IL-2 signaling in the presence
of daclizumab, leading to their proliferation (Martin et al., 2010;
Bielekova, 2013).
Thus, while therapies such as GA or IFN-β do not primarily
target NK cells but have effects on multiple immune cell types, it
appears that expansion of the regulatory CD56bright population
of NK cells via intermediate IL-2 receptor signaling is an impor-
tant biological effect of daclizumab treatment (Kala et al., 2011;
Kieseier and Stuve, 2011; Martin, 2012).
FURTHER MONOCLONAL ANTIBODY THERAPIES, ALEMTUZUMAB, AND
RITUXIMAB
Natural Killer cells were shown to mediate a lytic attack (antibody-
dependent cellular cytotoxicity, ADCC) through binding to
FcγRIII receptor (CD16) (Perussia et al., 1984). Several in vivo
and clinical studies assessed the pivotal role of ADCC by NK
cells in tumor treatments using monoclonal antibodies (Clynes
et al., 2000). Alemtuzumab is a humanized monoclonal anti-
body against CD52, a surface antigen of normal and malignant
lymphocytes. It is approved for the treatment of B cell chronic
lymphocytic leukemia and is undergoing phase III clinical trials
for MS. Treatment of mice with this substance results in dose-
dependent depletion of B and T lymphocytes from the circulation.
Cells with little expression of CD52 such as mature NK cells were
comparably less affected. Curiously, removal of NK cells essentially
ablated alemtuzumab activity, suggesting a prominent role for NK
cell-mediated ADCC in lymphocyte depletion by this therapy (Hu
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et al., 2009). Also, rituximab is a chimeric monoclonal antibody,
which targets the CD20 antigen on pre B cells and B cells. Although
NK cells have not been investigated in MS during this treatment,
ADCC by NK cells was previously described to be an essential
therapeutic mechanism of rituximab in lupus treatment (Anolik
et al., 2003). Moreover, rituximab clinical outcome in cancer was
associated with a polymorphism inducing a variation in receptor
affinity of the FcγRIII (Dall’Ozzo et al., 2004; Veeramani et al.,
2011).
REGULATION OF AUTOIMMUNITY BY NK CELLS IN MULTIPLE
SCLEROSIS
Regulation of autoimmunity by NK cells can occur through secre-
tion of cytokines and the effect of those cytokines in the local
milieu or through cytolytic deletion of effector cells such as T cells
and/or antigen-presenting cells.
Disease-modifying therapies for MS that have an effect on NK
cells tend to increase the CD56bright CD16− “immature” NK cell
population in peripheral blood. In contrast, very little is known
about the role of NK cell cytolytic activity in dampening autoim-
munity in MS. While published studies have demonstrated that
there are transient cyclical deficits in NK cell cytolytic competence
as assessed by functional assay, the targets in vivo are only just
beginning to be elucidated. As mentioned earlier, dendritic cells
may be targets of NK cell cytotoxicity designed to dampen autoim-
munity by editing antigen presentation, at least when treated
with GA.
Nielsen et al. (2012) have studied the ability of CD56bright
and CD56dim NK cells to kill autologous activated CD4+ T cells
through the granule exocytosis pathway. They found that both
subsets efficiently killed activated, but not resting, CD4+ T cells.
Degranulation of NK cells toward activated CD4+ T cells was
enhanced by IL-2, IL-15, IL-12+ IL-18, and IFN-α, however, IL-7
and IL-21 stimulated degranulation by CD56bright NK cells but
not by CD56dim NK cells.
Recently, Jiang et al. (2011) have demonstrated that CD56bright
NK cells can lyze activated T cells through a granzyme K mediated
mechanism. These NK cells degranulate to cause caspase indepen-
dent apoptosis and mitochondrial dysfunction in activated T cells
by preferential transfer of granzyme K. Gene silencing of granzyme
K with siRNA abrogated the ability of a CD56bright human NK
cell line to kill syngeneic activated T cells. These authors also
showed that treatment of MS patients with daclizumab signifi-
cantly enhanced this mechanism of cytotoxicity by CD56bright NK
cells.
The evidence for NK cell regulation of autoimmune effec-
tor cells by cytolytic deletion in MS is sparse but intriguing and
will undoubtedly provoke more studies. The deficit of NK killing
activity in MS has not been explained at the molecular level. As
cytolysis of target cells by NK cells is mediated by one of two dis-
tinct molecular mechanisms, the death receptor pathway and the
granule exocytosis pathway, it could be expected that molecular
components of either pathway may be involved.
The death receptor pathway is mediated by membrane-bound
or soluble factors belonging to the TNF superfamily that inter-
act with one of the membrane-bound TNF-receptor (TNFR)
superfamily agents (MacEwan, 2002). Trimerization of TNFRs
[e.g., TNFR1, Fas, and TNF-related apoptosis-inducing ligand
(TRAIL) receptors] activates death-domains in their intracellular
tails, which leads to activation of caspases and cell death. The gran-
ule exocytosis pathway is dependent on the pore-forming protein
perforin, which allows passage of serine proteases (granzymes)
into the cytoplasm of target cells (Catalfamo and Henkart, 2003).
Granzymes induce cell death either through caspase dependent
apoptosis or mitochondrial injury.
At the 2012 meeting of the Society for Natural Immunity, we
presented experimental results from a cross sectional study indi-
cating that untreated MS patients had a relative deficiency of
CD16+Perforin+ NK cells relative to apparently healthy controls
(Nayak and Jacolik, 2012). A threshold level of CD16+/Perforin+
lymphocytes was found at 75%. Ninety one percent of appar-
ently healthy controls had greater than 75% CD16+/perforin+
lymphocytes in comparison with 50% of untreated MS subjects.
CD16+/perforin+ lymphocytes in glatiramer acetate treated MS
subjects were not statistically different from apparently healthy
controls, a finding that is consistent with the study reported by
Sand et al. (2009) demonstrating increased killing by GA-treated
NK cells. No difference in CD16+/Perforin+ lymphocytes was seen
in stroke patients. Low levels of CD16+/Perforin+ lymphocytes
has not yet been correlated with the killing deficit in MS but could
potentially begin to provide an explanation for this deficit in MS.
CONCLUDING REMARKS
The role of NK cells in dampening autoimmunity and the mech-
anisms by which this is achieved is of particular interest from
a therapeutic point of view. The differential effects of cytokines
such as IL-7 and IL-21 in stimulating granule dependent killing
in NK cell subpopulations hints at the complexity of regulation
of NK cell-mediated cytotoxicity and the potential importance
of tissue specific microenvironments in determining functional
activity. Of particular importance may be the generation of tran-
sient changes in cytokine profiles that may lead to temporary
deficits in NK cell killing activity that has been reported to cor-
relate with clinical exacerbations and radiological disease activity
in MS. The current disease-modifying therapies have been devel-
oped to have a salutary effect on clinical endpoints and so the
mechanisms of action remain an object of study after they are
in clinical use. Many of the current disease-modifying therapies
for MS do have effects on NK cells. However, as more becomes
known about how NK cells are regulated in normal and diseased
tissues, therapeutic development may specifically target processes
that regulate NK cell functions. For example, compounds that
increase the proportion of CD16+Perforin+ NK cells may prevent
disease relapses and targeted expression of IL-7 and CD21 may
provide competency signals that convert CD56bright NK cells from
a predominantly cytokine producing cell type to an efficient cyto-
toxic cell type. This may also be particularly beneficial in tumors
where infiltrating NK cells are predominantly CD56bright cytokine
producing cells (Carrega et al., 2008). In recent years, NK cells
have emerged as potential biological markers for the response
to different MS therapies, including IFN-β, mitoxantrone, and
daclizumab. Notably, the immunoregulatory and immature NK
cell subset CD56bright seems to play an important role in the resolu-
tion of MS and to mediate the beneficial effects of several therapies,
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potentially via modulation of T cell responses. A paradox rises
between treatments promoting a more immature NK cell pheno-
type in the periphery, such as IFN-β, natalizumab, and daclizumab,
also linked to a positive clinical outcome; and those inducing a
more mature phenotype, such as mitoxantrone and fingolimod.
The increased number of CD56bright NK cells after treatment
could result from a diminished maturation rate of CD56bright
toward CD56dim NK cells, as those have been described by Romag-
nani et al. (2007) as being able to maturate into CD56dim cells upon
activation. Further possible mechanisms of CD56bright expansion
include differential homing of NK cell populations following treat-
ment, leading to an increased output of immature CD56bright
NK cells from lymphoid organs into the peripheral circulation.
Although trafficking of NK cells has been extensively studied in
the mouse (Gregoire et al., 2007), human data are scarce (Carrega
and Ferlazzo, 2012) and so far, only speculative.
Taken together, these studies highlight the importance of the
regulatory role of NK cells in the immunopathology of MS. More-
over, the precise beneficial NK cell phenotype that should be
targeted in MS remains to be determined.
REFERENCES
Aktas, O., Ullrich, O., Infante-Duarte,
C., Nitsch, R., and Zipp, F. (2007).
Neuronal damage in brain inflam-
mation. Arch. Neurol. 64, 185–189.
Al-Falahi, Y., Sand, K. L., Knudsen, E.,
Damaj, B. B., Rolin, J., and Mag-
hazachi, A. A. (2009). Splenic nat-
ural killer cell activity in two mod-
els of experimental neurodegenera-
tive diseases. J. Cell. Mol. Med. 13,
2693–2703.
Anolik, J. H., Campbell, D., Felgar, R.
E., Young, F., Sanz, I., Rosenblatt,
J., et al. (2003). The relationship of
FcgammaRIIIa genotype to degree
of B cell depletion by rituximab
in the treatment of systemic lupus
erythematosus. Arthritis Rheum. 48,
455–459.
Bar-Or, A. (2008). The immunology of
multiple sclerosis. Semin. Neurol. 28,
29–45.
Benczur, M., Petranyl, G. G., Palffy, G.,
Varga, M., Talas, M., Kotsy, B., et al.
(1980). Dysfunction of natural killer
cells in multiple sclerosis: a possi-
ble pathogenetic factor. Clin. Exp.
Immunol. 39, 657–662.
Bielekova, B. (2013). Daclizumab ther-
apy for multiple sclerosis. Neurother-
apeutics 10, 55–67.
Bielekova, B., Catalfamo, M., Reichert-
Scrivner, S., Packer, A., Cerna, M.,
Waldmann, T. A., et al. (2006). Reg-
ulatory CD56(bright) natural killer
cells mediate immunomodulatory
effects of IL-2Ralpha-targeted ther-
apy (daclizumab) in multiple sclero-
sis. Proc. Natl. Acad. Sci. U.S.A. 103,
5941–5946.
Bielekova, B., Howard, T., Packer, A. N.,
Richert, N., Blevins, G., Ohayon, J., et
al. (2009). Effect of anti-CD25 anti-
body daclizumab in the inhibition
of inflammation and stabilization
of disease progression in multiple
sclerosis. Arch. Neurol. 66, 483–489.
Bielekova, B., Richert, N., Herman,
M. L., Ohayon, J., Waldmann, T.
A., McFarland, H., et al. (2011).
Intrathecal effects of daclizumab
treatment of multiple sclerosis. Neu-
rology 77, 1877–1886.
Bielekova, B., Richert, N., Howard,
T., Blevins, G., Markovic-Plese, S.,
McCartin, J., et al. (2004). Human-
ized anti-CD25 (daclizumab)
inhibits disease activity in multiple
sclerosis patients failing to respond
to interferon beta. Proc. Natl. Acad.
Sci. U.S.A. 101, 8705–8708.
Carrega, P., and Ferlazzo, G. (2012).
Natural killer cell distribution
and trafficking in human tis-
sues. Front. Immunol. 3:347.
doi:10.3389/fimmu.2012.00347
Carrega, P., Morandi, B., Costa, R.,
Frumento, G., Forte, G., Altavilla,
G., et al. (2008). Natural killer
cells infiltrating human nonsmall-
cell lung cancer are enriched in
CD56 bright CD16(-) cells and dis-
play an impaired capability to kill
tumor cells. Cancer 112, 863–875.
Catalfamo, M., and Henkart, P. A.
(2003). Perforin and the gran-
ule exocytosis cytotoxicity pathway.
Curr. Opin. Immunol. 15, 522–527.
Chanvillard, C., Millward, J. M.,
Lozano, M., Hamann, I., Paul,
F., Zipp, F., et al. (2012). Mitox-
antrone induces natural killer
cell maturation in patients with
secondary progressive multiple
sclerosis. PLoS ONE 7:e39625.
doi:10.1371/journal.pone.0039625
Clanet, M. (2008). Jean-Martin Char-
cot. 1825 to 1893. Int. MS J. 15,
59–61.
Clynes, R. A., Towers, T. L., Presta, L. G.,
and Ravetch, J. V. (2000). Inhibitory
Fc receptors modulate in vivo cyto-
toxicity against tumor targets. Nat.
Med. 6, 443–446.
Constantinescu, C. S., Farooqi,
N., O’Brien, K., and Gran, B.
(2011). Experimental autoimmune
encephalomyelitis (EAE) as a model
for multiple sclerosis (MS). Br. J.
Pharmacol. 164, 1079–1106.
Dalbeth, N., Gundle, R., Davies, R. J.,
Lee, Y. C., McMichael, A. J., and
Callan,M. F. (2004). CD56bright NK
cells are enriched at inflammatory
sites and can engage with monocytes
in a reciprocal program of activa-
tion. J. Immunol. 173, 6418–6426.
Dall’Ozzo, S., Tartas, S., Paintaud, G.,
Cartron, G., Colombat, P., Bardos, P.,
et al. (2004). Rituximab-dependent
cytotoxicity by natural killer cells:
influence of FCGR3A polymor-
phism on the concentration-effect
relationship. Cancer Res. 64,
4664–4669.
Degli-Esposti, M. A., and Smyth, M. J.
(2005). Close encounters of different
kinds: dendritic cells and NK cells
take centre stage. Nat. Rev. Immunol.
5, 112–124.
Ferlazzo, G., and Munz, C. (2004). NK
cell compartments and their activa-
tion by dendritic cells. J. Immunol.
172, 1333–1339.
Ferlazzo, G., Thomas, D., Lin, S. L.,
Goodman, K., Morandi, B., Muller,
W. A., et al. (2004). The abundant
NK cells in human secondary lym-
phoid tissues require activation to
express killer cell Ig-like receptors
and become cytolytic. J. Immunol.
172, 1455–1462.
Ferlazzo, G., Tsang, M. L., Moretta,
L., Melioli, G., Steinman, R. M.,
and Munz, C. (2002). Human den-
dritic cells activate resting natural
killer (NK) cells and are recognized
via the NKp30 receptor by acti-
vated NK cells. J. Exp. Med. 195,
343–351.
Gan, Y., Liu, R., Wu, W., Bomprezzi,
R., and Shi, F. D. (2012). Antibody
to alpha4 integrin suppresses nat-
ural killer cells infiltration in cen-
tral nervous system in experimen-
tal autoimmune encephalomyelitis.
J. Neuroimmunol. 247, 9–15.
Gandhi, R., Laroni, A., and Weiner, H. L.
(2010). Role of the innate immune
system in the pathogenesis of multi-
ple sclerosis. J. Neuroimmunol. 221,
7–14.
Gregoire, C., Chasson, L., Luci, C.,
Tomasello, E., Geissmann, F., Vivier,
E., et al. (2007). The trafficking of
natural killer cells. Immunol. Rev.
220, 169–182.
Hamann, I., Dorr, J., Glumm, R.,
Chanvillard, C., Janssen, A.,
Millward, J. M., et al. (2012).
Characterization of natural killer
cells in paired CSF and blood
samples during neuroinflammation.
J. Neuroimmunol.
Hamann, I., Unterwalder, N., Cardona,
A. E., Meisel, C., Zipp, F., Ranso-
hoff, R. M., et al. (2011). Analyses of
phenotypic and functional charac-
teristics of CX3CR1-expressing nat-
ural killer cells. Immunology 133,
62–73.
Hao, J., Campagnolo, D., Liu, R.,
Piao, W., Shi, S., Hu, B., et al.
(2011). Interleukin-2/interleukin-2
antibody therapy induces target
organ natural killer cells that
inhibit central nervous system
inflammation. Ann. Neurol. 69,
721–734.
Hartrich, L., Weinstock-Guttman, B.,
Hall, D., Badgett, D., Baier, M.,
Patrick, K., et al. (2003). Dynam-
ics of immune cell trafficking
in interferon-beta treated multiple
sclerosis patients. J. Neuroimmunol.
139, 84–92.
Hu, Y., Turner, M. J., Shields, J., Gale,
M. S., Hutto, E., Roberts, B. L., et al.
(2009). Investigation of the mech-
anism of action of alemtuzumab
in a human CD52 transgenic
mouse model. Immunology 128,
260–270.
Infante-Duarte, C., Weber, A.,
Kratzschmar, J., Prozorovski, T.,
Pikol, S., Hamann, I., et al. (2005).
Frequency of blood CX3CR1-
positive natural killer cells correlates
with disease activity in multiple
sclerosis patients. FASEB J. 19,
1902–1904.
Jiang, W., Chai, N. R., Maric, D., and
Bielekova, B. (2011). Unexpected
role for granzyme K in CD56bright
NK cell-mediated immunoregu-
lation of multiple sclerosis. J.
Immunol. 187, 781–790.
Johnson, T. A., Evans, B. L., Durafourt,
B. A., Blain, M., Lapierre, Y.,
Bar-Or, A., et al. (2011). Reduc-
tion of the peripheral blood
CD56(bright) NK lymphocyte
subset in FTY720-treated multiple
sclerosis patients. J. Immunol. 187,
570–579.
www.frontiersin.org March 2013 | Volume 4 | Article 63 | 7
Chanvillard et al. NK cells in multiple sclerosis
Kala, M., Miravalle, A., and Vollmer,
T. (2011). Recent insights into
the mechanism of action of glati-
ramer acetate. J. Neuroimmunol. 235,
9–17.
Kappos, L., Antel, J., Comi, G., Montal-
ban, X., O’Connor, P., Polman, C.
H., et al. (2006). Oral fingolimod
(FTY720) for relapsing multiple
sclerosis. N. Engl. J. Med. 355,
1124–1140.
Kastrukoff, L. F., Lau, A., Wee, R., Zec-
chini, D., White, R., and Paty, D. W.
(2003). Clinical relapses of multiple
sclerosis are associated with ‘novel’
valleys in natural killer cell func-
tional activity. J. Neuroimmunol.
145, 103–114.
Kastrukoff, L. F., Morgan, N. G., Zec-
chini, D., White, R., Petkau, A. J.,
Satoh, J., et al. (1998). A role for nat-
ural killer cells in the immunopatho-
genesis of multiple sclerosis. J. Neu-
roimmunol. 86, 123–133.
Kastrukoff, L. F., Morgan, N. G., Zec-
chini, D., White, R., Petkau, A. J.,
Satoh, J., et al. (1999). Natural killer
cells in relapsing-remitting MS:
effect of treatment with interferon
beta-1B. Neurology 52, 351–359.
Kent, S. J., Karlik, S. J., Cannon, C.,
Hines, D. K., Yednock, T. A., Fritz,
L. C., et al. (1995). A monoclonal
antibody to alpha 4 integrin sup-
presses and reverses active experi-
mental allergic encephalomyelitis. J.
Neuroimmunol. 58, 1–10.
Kieseier, B. C., and Stuve, O. (2011). A
critical appraisal of treatment deci-
sions in multiple sclerosis – old
versus new. Nat. Rev. Neurol. 7,
255–262.
Korn, T., Magnus, T., Toyka, K., and
Jung, S. (2004). Modulation of effec-
tor cell functions in experimental
autoimmune encephalomyelitis by
leflunomide – mechanisms inde-
pendent of pyrimidine depletion. J.
Leukoc. Biol. 76, 950–960.
Korn, T., Toyka, K., Hartung, H. P.,
and Jung, S. (2001). Suppression
of experimental autoimmune neu-
ritis by leflunomide. Brain 124,
1791–1802.
Kowarik, M. C., Pellkofer, H. L., Cepok,
S., Korn, T., Kumpfel, T., Buck, D., et
al. (2011). Differential effects of fin-
golimod (FTY720) on immune cells
in the CSF and blood of patients with
MS. Neurology 76, 1214–1221.
Lim, S. Y., and Constantinescu, C. S.
(2010). Current and future disease-
modifying therapies in multiple
sclerosis. Int. J. Clin. Pract. 64,
637–650.
MacEwan, D. J. (2002). TNF ligands and
receptors – a matter of life and death.
Br. J. Pharmacol. 135, 855–875.
Manda, G., Neagu, M., Constantin, C.,
Neagoe, I., and Codreanu, C. (2009).
Preliminary study on the immuno-
logic background of good clini-
cal outcome in rheumatoid arthri-
tis patients after one month therapy
with leflunomide. Rheumatol. Int.
29, 937–946.
Martin, J. F., Perry, J. S., Jakhete, N. R.,
Wang, X., and Bielekova, B. (2010).
An IL-2 paradox: blocking CD25 on
T cells induces IL-2-driven activa-
tion of CD56(bright) NK cells. J.
Immunol. 185, 1311–1320.
Martin, R. (2012). Anti-CD25
(daclizumab) monoclonal anti-
body therapy in relapsing-remitting
multiple sclerosis. Clin. Immunol.
142, 9–14.
Martinez-Rodriguez, J. E., Lopez-Botet,
M., Munteis, E., Rio, J., Roquer, J.,
Montalban, X., et al. (2011). Nat-
ural killer cell phenotype and clinical
response to interferon-beta therapy
in multiple sclerosis. Clin. Immunol.
141, 348–356.
Martinez-Rodriguez, J. E., Saez-
Borderias, A., Munteis, E., Romo,
N., Roquer, J., and Lopez-Botet,
M. (2010). Natural killer receptors
distribution in multiple sclerosis:
relation to clinical course and
interferon-beta therapy. Clin.
Immunol. 137, 41–50.
Merrill, J., Jondal, M., Seeley, J., Ullberg,
M., and Siden, A. (1982). Decreased
NK killing in patients with mul-
tiple sclerosis: an analysis on the
level of the single effector cell in
peripheral blood and cerebrospinal
fluid in relation to the activity in
the disease. Clin. Exp. Immunol. 47,
419–430.
Miller, D. H., Khan, O. A., Sheremata,
W. A., Blumhardt, L. D., Rice, G.
P., Libonati, M. A., et al. (2003). A
controlled trial of natalizumab for
relapsing multiple sclerosis. N. Engl.
J. Med. 348, 15–23.
Morandi,B.,Bramanti,P.,Bonaccorsi, I.,
Montalto, E., Oliveri, D., Pezzino, G.,
et al. (2008). Role of natural killer
cells in the pathogenesis and pro-
gression of multiple sclerosis. Phar-
macol. Res. 57, 1–5.
Moretta, A. (2002). Natural killer cells
and dendritic cells: rendezvous in
abused tissues. Nat. Rev. Immunol.
2, 957–964.
Nayak, R. C., and Jacolik, R. F.
(2012). “CD16+/perforin+ lympho-
cytes (NK cells) regulate autoimmu-
nity in multiple sclerosis by cytolysis
of antigen laden cells in the periph-
eral blood (abstract #178),”Presented
at The Society for Natural Immunity
Meeting, Asilomar. Available at: http:
//nk2012.wordpress.com/abstracts/
Neighbour, P. A., Grayzel, A. I., and
Miller, A. E. (1982). Endogenous
and interferon-augmented nat-
ural killer cell activity of human
peripheral blood mononuclear
cells in vitro. Studies of patients
with multiple sclerosis, systemic
lupus erythematosus or rheumatoid
arthritis. Clin. Exp. Immunol. 49,
11–21.
Nielsen, N., Odum, N., Urso, B., Lanier,
L. L., and Spee, P. (2012). Cyto-
toxicity of CD56(bright) NK cells
towards autologous activated CD4+
T cells is mediated through NKG2D,
LFA-1 and TRAIL and damp-
ened via CD94/NKG2A. PLoS ONE
7:e31959. doi:10.1371/journal.pone.
0031959
Nordqvist, C. (2012). Aubagio (teri-
flunomide) approved for multiple
sclerosis treatment, FDA. Med-
ical News Today. Available at:
http://www.medicalnewstoday.com/
articles/250293.php
Oger, J., Kastrukoff, L. F., Li, D. K., and
Paty, D. W. (1988). Multiple scle-
rosis: in relapsing patients, immune
functions vary with disease activity
as assessed by MRI. Neurology 38,
1739–1744.
Perini, P., Wadhwa, M., Buttarello, M.,
Meager, A., Facchinetti, A., Thorpe,
R., et al. (2000). Effect of IFNbeta
and anti-IFNbeta antibodies on NK
cells in multiple sclerosis patients. J.
Neuroimmunol. 105, 91–95.
Perry, J. S., Han, S., Xu, Q., Herman,
M. L., Kennedy, L. B., Csako, G.,
et al. (2012). Inhibition of LTi cell
development by CD25 blockade is
associated with decreased intrathe-
cal inflammation in multiple sclero-
sis. Sci. Transl. Med. 4, 145ra106.
Perussia, B., Trinchieri, G., Jackson, A.,
Warner, N. L., Faust, J., Rumpold,
H., et al. (1984). The Fc receptor
for IgG on human natural killer
cells: phenotypic, functional, and
comparative studies with mono-
clonal antibodies. J. Immunol. 133,
180–189.
Planas, R., Jelcic, I., Schippling, S., Mar-
tin, R., and Sospedra, M. (2012).
Natalizumab treatment perturbs
memory- and marginal zone-like B-
cell homing in secondary lymphoid
organs in multiple sclerosis. Eur. J.
Immunol. 42, 790–798.
Putzki, N., Baranwal, M. K., Tettenborn,
B., Limmroth, V., and Kreuzfelder,
E. (2010). Effects of natalizumab on
circulating B cells, T regulatory cells
and natural killer cells. Eur. Neurol.
63, 311–317.
Ransohoff, R. M. (2007). Natalizumab
for multiple sclerosis. N. Engl. J. Med.
356, 2622–2629.
Romagnani, C., Juelke, K., Falco, M.,
Morandi, B., D’Agostino, A., Costa,
R., et al. (2007). CD56brightCD16-
killer Ig-like receptor-NK cells dis-
play longer telomeres and acquire
features of CD56dim NK cells
upon activation. J. Immunol. 178,
4947–4955.
Sand, K. L., Knudsen, E., Rolin, J.,
Al-Falahi, Y., and Maghazachi, A.
A. (2009). Modulation of nat-
ural killer cell cytotoxicity and
cytokine release by the drug glati-
ramer acetate. Cell. Mol. Life Sci. 66,
1446–1456.
Saraste, M., Irjala, H., and Airas, L.
(2007). Expansion of CD56Bright
natural killer cells in the peripheral
blood of multiple sclerosis patients
treated with interferon-beta. Neurol.
Sci. 28, 121–126.
Shi, F. D., Takeda, K., Akira, S., Sarvet-
nick, N., and Ljunggren, H. G.
(2000). IL-18 directs autoreactive
T cells and promotes autodestruc-
tion in the central nervous sys-
tem via induction of IFN-gamma
by NK cells. J. Immunol. 165,
3099–3104.
Skarica, M., Eckstein, C., Whartenby, K.
A., and Calabresi, P. A. (2011). Novel
mechanisms of immune modulation
of natalizumab in multiple sclero-
sis patients. J. Neuroimmunol. 235,
70–76.
Spits, H., Artis, D., Colonna, M., Diefen-
bach, A., Di Santo, J. P., Eberl, G., et
al. (2013). Innate lymphoid cells –
a proposal for uniform nomen-
clature. Nat. Rev. Immunol. 13,
145–149.
Spits, H., and Di Santo, J. P. (2011).
The expanding family of innate lym-
phoid cells: regulators and effectors
of immunity and tissue remodeling.
Nat. Immunol. 12, 21–27.
Strowig, T., Brilot, F., and Munz, C.
(2008). Noncytotoxic functions of
NK cells: direct pathogen restriction
and assistance to adaptive immunity.
J. Immunol. 180, 7785–7791.
Vaessen, L. M., Van Besouw, N. M.,
Mol, W. M., Ijzermans, J. N., and
Weimar, W. (2006). FTY720 treat-
ment of kidney transplant patients:
a differential effect on B cells,
naive T cells, memory T cells and
NK cells. Transpl. Immunol. 15,
281–288.
Vandenbark, A. A., Huan, J., Agotsch,
M., La Tocha, D., Goelz, S., Offner,
H., et al. (2009). Interferon-
beta-1a treatment increases
CD56bright natural killer cells
and CD4+CD25+ Foxp3 expres-
sion in subjects with multiple
sclerosis. J. Neuroimmunol. 215,
125–128.
Frontiers in Immunology | NK Cell Biology March 2013 | Volume 4 | Article 63 | 8
Chanvillard et al. NK cells in multiple sclerosis
Veeramani, S., Wang, S. Y., Dahle, C.,
Blackwell, S., Jacobus, L., Knut-
son, T., et al. (2011). Rituximab
infusion induces NK activation in
lymphoma patients with the high-
affinity CD16 polymorphism. Blood
118, 3347–3349.
Weber, M. S., Hohlfeld, R., and Zamvil,
S. S. (2007). Mechanism of action
of glatiramer acetate in treatment of
multiple sclerosis. Neurotherapeutics
4, 647–653.
Wynn, D., Kaufman, M., Montalban,
X., Vollmer, T., Simon, J., Elkins,
J., et al. (2010). Daclizumab in
active relapsing multiple sclero-
sis (CHOICE study): a phase 2,
randomised, double-blind, placebo-
controlled, add-on trial with
interferon beta. Lancet Neurol. 9,
381–390.
Xu, W., Fazekas, G., Hara, H., and
Tabira, T. (2005). Mechanism of
natural killer (NK) cell regula-
tory role in experimental autoim-
mune encephalomyelitis. J. Neu-
roimmunol. 163, 24–30.
Yednock, T. A., Cannon, C., Vandevert,
C., Goldbach, E. G., Shaw, G.,
Ellis, D. K., et al. (1995). Alpha
4 beta 1 integrin-dependent
cell adhesion is regulated by a
low affinity receptor pool that
is conformationally responsive
to ligand. J. Biol. Chem. 270,
28740–28750.
Yong, V. W. (2002). Differential mech-
anisms of action of interferon-beta
and glatiramer aetate in MS. Neurol-
ogy 59, 802–808.
Zhang, B., Yamamura, T., Kondo,
T., Fujiwara, M., and Tabira, T.
(1997). Regulation of experimental
autoimmune encephalomyelitis by
natural killer (NK) cells. J. Exp. Med.
186, 1677–1687.
Conflict of Interest Statement: Ramesh
C. Nayak and Raymond F. Jacolik are
employees of MSDx Inc. and own shares
in MSDx Inc.
Received: 31 October 2012; paper pending
published: 20 December 2012; accepted:
27 February 2013; published online: 13
March 2013.
Citation: Chanvillard C, Jacolik RF,
Infante-Duarte C and Nayak RC (2013)
The role of natural killer cells in
multiple sclerosis and their therapeutic
implications. Front. Immunol. 4:63. doi:
10.3389/fimmu.2013.00063
This article was submitted to Frontiers in
NK Cell Biology, a specialty of Frontiers
in Immunology.
Copyright © 2013 Chanvillard, Jacolik,
Infante-Duarte and Nayak. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distrib-
ution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org March 2013 | Volume 4 | Article 63 | 9
